Welcome to the TIGIT Therapies Digital Summit
The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings.
As evidence of TIGIT’s clinical potential builds, the TIGIT Therapies Digital Summit brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI.
Hear from leaders in TIGIT development from Merck, Compugen, iTeos Therapeutics, Agenus and more!
Who Will You Meet?
World-Class Speaker Faculty
Vijay Kuchroo
Director, Evergrande Center for Immunologic Diseases
Harvard Medical School and Brigham and Women’s Hospital
Proud to Partner With:
"Please join me at the meeting as we unravel the role TIGIT plays in promoting immune suppression in the tumor microenvironment and how we are leveraging these novel discoveries to build more effective TIGIT therapies for patients."
Dhan Chand, Scientific Director, Head of Drug Discovery, Agenus